Thomas Lau
18 posts

Thomas Lau
@ThomKLau
bioengineering @stanford @arcinstitute, prev @ emerald cloud lab

Multiplexed in vivo screening is the future of drug development. @ManifoldBio is multiplexing protein therapies in vivo. @GordianBio is multiplexing gene therapies in vivo. @waypointbio is multiplexing cell therapies in vivo. GT Bio is multiplexing LNPs in vivo. 50Y portcos all











We’ve decided to treat this launch as High Capability in the Biological and Chemical domain under our Preparedness Framework, and activated the associated safeguards. This is a precautionary approach, and we detail our safeguards in the system card. We outlined our approach on preparing for future AI capabilities in biology through a blog post earlier this month. openai.com/index/preparin…



Y Combinator is being criticized after it backed an AI startup that admits it basically cloned another AI startup tcrn.ch/3TQS9qj














